Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - thiotepa, quantity: 400 mg - injection, solvent for - excipient ingredients: sodium chloride; water for injections - tepadina is indicated, in combination with other chemotherapy medicinal products: ? with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients; ? when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients (refer to section 5.1 pharmacodynamic properties - clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - thiotepa, quantity: 15 mg - injection, powder for - excipient ingredients: - tepadina is indicated, in combination with other chemotherapy medicinal products: ? with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients; ? when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients (refer to section 5.1 pharmacodynamic properties - clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - thiotepa, quantity: 100 mg - injection, powder for - excipient ingredients: - tepadina is indicated, in combination with other chemotherapy medicinal products: ? with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients; ? when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients (refer to section 5.1 pharmacodynamic properties - clinical trials).

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

adienne pharma & biotech - thiotepa - powder for solution for infusion - 15mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

adienne pharma & biotech - thiotepa - powder for solution for infusion - 100mg

New Zealand - English - Medsafe (Medicines Safety Authority)

link pharmaceuticals ltd - thiotepa 100mg - powder for injection - 100 mg - active: thiotepa 100mg - indicated, in combination with other chemotherapy medicinal products: - with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;

New Zealand - English - Medsafe (Medicines Safety Authority)

link pharmaceuticals ltd - thiotepa 15mg - powder for injection - 15 mg - active: thiotepa 15mg - indicated, in combination with other chemotherapy medicinal products: - with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;

New Zealand - English - Medsafe (Medicines Safety Authority)

link pharmaceuticals ltd - thiotepa 400mg - powder for injection with diluent - 400 mg - active: thiotepa 400mg excipient: sodium chloride water for injection - indicated, in combination with other chemotherapy medicinal products: - with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;

Canada - English - Health Canada

lederle cyanamid canada inc. - thiotepa - powder for solution - 15mg - thiotepa 15mg - antineoplastic agents

Israel - English - Ministry of Health

mbi pharma ltd., israel - thiotepa - powder for concentrate for solution for infusion - thiotepa 100 mg - thiotepa - tepadina is indicated, in combination with other chemotherapy medicinal products:1. with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;2. when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.